Activated protein C (APC) resistance1 due to the factor V (FV) gene mutation G1691A (single-letter nucleotide codes)2 and the prothrombin gene mutation G20210A3 are the most common genetic disorders associated with venous thrombosis. APC resistance not due to the FV gene mutation G1691A,4,5 and the hyperprothrombinemia secondary to the prothrombin gene mutation G20210A,3 are also independent risk factors for venous thrombosis. Although it has been surmised that high levels of prothrombin in plasma may result in an increased rate of thrombin generation6 or increased thrombin potential,7 little is known on how hyperprothrombinemia leads to venous thrombosis. Recently, Smirnov and colleagues reported on an additional mechanism that might contribute to the pathogenetic role of hyperprothrombinemia.8 They showed that prothrombin may act as a modulator of the anticoagulant activity of APC both in a purified system and in plasma by inhibiting the ability of APC to inactivate FVa.

On the basis of this observation, one would predict that individuals with hyperprothrombinemia might also have acquired APC resistance as measured with the common aPTT-based test. To test this hypothesis, we selected from our files data on 285 individuals who served as controls in a previous study designed to assess the prevalence of the prothrombin gene mutation G20210A in our patient population.9 Individuals included in the analysis were those for whom APC resistance and prothrombin levels were available and those who were not carriers of the FV gene mutation G1691A. APC resistance was measured with the original aPTT-based test described by Dahlback et al1 as modified by Faioni et al10; results were expressed as normalized APC ratios (n-APC-ratios) against a frozen pooled normal plasma. Prothrombin was measured using S-2238 (Chromogenix, Mölndal, Sweden) as substrate and Echis Carinatus (Sigma, St Louis, MO) as activator11; results were expressed as U/dL against a pooled normal plasma arbitrarily set at 100 U/dL.

As shown in the figure, there was an inverse relationship between n-APC-ratios and prothrombin activity (r = −0.32, P < .001). In particular, 7 of the 60 subjects (12%) with prothrombin levels higher than the 80th percentile (ie, 110 U/dL) had n-APC-ratios lower than the lower limit for APC resistance (ie, 0.76) established for this method at our laboratory. In contrast, only 2 of the 225 subjects (1%) with prothrombin levels lower than the 80th percentile had n-APC ratios lower than the lower limit (P < .0001, Fisher exact test). These results support the view that plasma prothrombin is a determinant of APC resistance and may explain the mechanism through which hyperprothrombinemia is associated with an increased risk for venous thrombosis.

Fig. 1.

Normalized activated protein C ratios as a function of prothrombin levels in subjects without the FV gene mutation G1691A.

n-APC-ratios are inversely correlated to prothrombin levels (r = −0.32, P < .001).

Fig. 1.

Normalized activated protein C ratios as a function of prothrombin levels in subjects without the FV gene mutation G1691A.

n-APC-ratios are inversely correlated to prothrombin levels (r = −0.32, P < .001).

Close modal

Furthermore, these results indicate that hyperprothrombinemia is another determinant of acquired APC resistance, like high factor VIII (FVIII) plasma levels.12 We surmise, however, that high levels of the 2 proteins act through different mechanisms. Perhaps high FVIII levels act by increasing the procoagulant strength of plasma as measured by the aPTT, a test that is very responsive to high FVIII levels.12 In contrast, as shown by Smirnov and colleagues, prothrombin is likely to act directly by inhibiting APC.8 

1
Dahlback
B
Carlsson
M
Svensson
PJ
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proc Natl Acad Sci U S A.
90
1993
1004
1008
2
Bertina
RM
Koeleman
BP
Koster
T
et al
Mutation in blood coagulation factor V associated with resistance to activated protein C.
Nature.
369
1994
64
67
3
Poort
SR
Rosendaal
FR
Reitsma
PH
Bertina
RM
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
Blood.
88
1996
3698
3703
4
De Visser
MCH
Rosendaal
FR
Bertina
RM
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
Blood.
93
1999
1271
1276
5
Rodeghiero
F
Tosetto
A
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Ann Intern Med.
130
1999
643
650
6
Eikelboom
JW
Ivey
L
Ivey
J
Baker
RI
Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis.
Blood Coag Fibrinol.
10
1999
1
5
7
Kyrle
PA
Mannhalter
C
Beguin
S
et al
Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.
Arterioscl Thromb Vasc Biol.
18
1998
1287
1291
8
Smirnov
MD
Safa
O
Esmon
NL
Esmon
CT
Inhibition of activated protein C anticoagulant activity by prothrombin.
Blood
94
1999
3839
3846
9
Cattaneo
M
Chantarangkul
V
Taioli
E
Hermida-Santos
J
Tagliabue
L
The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.
Thromb Res.
93
1998
1
8
10
Faioni
EM
Franchi
F
Asti
D
Sacchi
E
Bernardi
F
Mannucci
PM
Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.
Thromb Haemost.
70
1993
1067
1071
11
Bertina
RM
van der Marel-van Niewkoop
W
Loeliger
EA
Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants.
Thromb Haemost.
42
1979
1296
1305
12
Laffan
MA
Manning
R
The influence of factor VIII on measurement of activated protein C resistance.
Blood Coag Fibrinol.
7
1996
761
765
Sign in via your Institution